NVAX Q3 2023 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M-97.0% YoY

Gross Profit

-$77M-348.4% margin

Operating Income

-$126M-569.4% margin

Net Income

-$131M-592.7% margin

EPS (Diluted)

$-1.26

QoQ Revenue Growth

-94.8%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$58M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$2.3B

Stockholders' Equity

-$678M

Cash & Equivalents

$651M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$735M	-97.0%
Gross Profit	-$77M	$300M	-125.6%
Operating Income	-$126M	-$127M	+1.2%
Net Income	-$131M	-$169M	+22.4%

Revenue Segments

Grant

$165M88%

Royalties and Other

$20M11%

Product

$2M1%

Geographic Segments

North America

$2M100%